LA JOLLA, Calif.
July 17, 2013
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting
RNAs, announced today the pricing of a public offering of 4,500,000 shares of its common stock at a price of
per share. The gross proceeds to Regulus from this offering are expected to be approximately
, before deducting underwriting discounts and commissions and estimated offering expenses payable by Regulus. The offering is expected to close on or about
July 22, 2013
, subject to customary closing conditions. Regulus has also granted the underwriters a 30-day option to purchase up to an additional 675,000 shares at the public offering price to cover overallotments, if any.
Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets Corp are acting as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow Life Sciences are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on
July 16, 2013
The offering is being made only by means of a prospectus, copies of which may be obtained from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48th Floor,
New York, NY
10112, Telephone: (800) 542-0970; from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue,
11717, Attn: Prospectus Department, Telephone: (631) 274-2806, Fax: 631-254-7140); or from BMO Capital Markets Corp, Attention: Equity Syndicate Department, 3 Times Square
New York, NY
10036, Telephone: (800) 414-3627, E-mail:
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.